LIFE:NGS-aTyr Pharma Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 2.88

Change

+0.20 (+7.46)%

Market Cap

USD 0.08B

Volume

0.09M

Analyst Target

USD 10.33
Analyst Rating

N/A

ducovest Verdict

Verdict

About

aTyr Pharma Inc is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.99 (+1.25%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

+7.16 (+0.80%)

USD 106.98B
MRNA Moderna Inc

+3.43 (+3.28%)

USD 38.83B
BNTX BioNTech SE

+0.48 (+0.55%)

USD 21.93B
ARGX argenx NV ADR

+6.33 (+1.72%)

USD 21.92B
GMAB Genmab AS

-0.41 (-1.42%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

+0.28 (+0.19%)

USD 18.44B
RPRX Royalty Pharma Plc

N/A

USD 18.18B
BGNE BeiGene Ltd

+8.05 (+6.15%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

+2.57 (+2.87%)

USD 16.06B

ETFs Containing LIFE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.94% 39% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.94% 38% F 39% F
Trailing 12 Months  
Capital Gain 443.60% 98% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 443.60% 98% N/A 99% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 73.47% 82% B 89% A-
Dividend Return 73.47% 82% B 88% B+
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 258.95% 5% F 3% F
Risk Adjusted Return 28.37% 64% D 41% F
Market Capitalization 0.08B 17% F 20% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 1.40 81% 56%
Price / Cash Flow Ratio -1.27 28% 67%
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity -86.92% 37% 14%
Return on Invested Capital -57.73% 53% 16%
Return on Assets -32.30% 44% 13%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.